Home
CBM588®

Teoliance

CBM588®

Name: CBM588®
SKU: PHY532
Price: 41.9 EUR
Availability: InStock

from €41.90

Exclusive Microbiota Strain

Skip to the end of the images gallery

Skip to the beginning of the images gallery

Teoliance

CBM588®

PHY532 - 90 tablets

Individually

Out of stock

€41.90 / unit

-8%

Pack of 3

Out of stock

€38.55 / unit

-8%

-11%

Pack of 6

Out of stock

€37.29 / unit

-11%

-13%

Subscription-13%

Pack of 2 Delivery: every 2 months

Out of stock

€36.45 / unit

-13%

€72.90 / 2 months

Payment in 3 instalments (no fees) or 4 instalments (with fees) on purchases of €50.00 or more (excluding subscriptions)

Free delivery from €59.00 onwards

100% secure payment

Exclusive Microbiota Strain

1.35 million CFUs* of Clostridium butyricum CBM588^®per 3 tablets
Clostridium butyricum CBM588^®: an exclusive probiotic strain, scientifically selected for its benefits on the microbiota and overall health

*CFU: Colony Forming Units
CBM588^® is a registered mark of Miyarisan.

Description

Why choose TEOLIANCE^® CBM588^® ?

TEOLIANCE^® CBM588^®is the result of an exclusive partnership with the Japanese laboratory that owns the strain. This partnership guarantees market exclusivity in France, with a precise dosage of 1.35 million CFU* per 3 tablets. This specific and unique strain, derived from decades of rigorous scientific research, has been developed in compliance with the highest quality and safety standards, fitting seamlessly into your daily routine.
*CFU : Colony-Forming Units

What does science say ?

Clostridium butyricum CBM588^®has been extensively studied, and its biological mechanism of action is well-documented in scientific literature. Numerous studies highlight its promising potential applications in health. However, to date, no health claims have been approved under European legislation.

Despite the lack of official recognition of specific benefits, this growing interest underscores promising perspectives that merit further exploration.

Key beenfits of TEOLIANCE^® CBM588^®

Teoliance^® CBM588^® is a dietary supplement formulated with an exclusive strain: Clostridium butyricum CBM588^®.

Some strains play an indirect but fundamental role in the production of short-chain fatty acids (SCFAs), such as butyrate. These SCFAs are naturally produced by gut bacteria during digestion, particularly through the fermentation of dietary fibers.

Scientifically selected strain

Clostridium butyricum CBM588^® a was chosen based on rigorous scientific studies demonstrating its effectiveness and unique properties. Discovered in Japan in 1933 by Dr. Miyairi, this strain has been the focus of research for decades. Clinical studies have validated its safe use, and its precise characteristics make CBM588^®a reliable and effective solution for improving digestive health.

Optimal dosage

The optimal dosage of Clostridium butyricum CBM588^® has been carefully selected to ensure both the efficacy and safety of the strain. Clinical studies established the necessary amount to deliver significant benefits while ensuring excellent tolerance. This guarantees that Teoliance^® CBM588^® provides optimal effects to meet all expectations.

Resistance to gastric acid, temperature, and antibiotics

Clostridium butyricum CBM588^® is a Gram-positive bacterium capable of producing spores, which grants it intrinsic resistance to stomach acid conditions, as confirmed by multiple studies. This property ensures the strain's protection and viability until it reaches its action site in the gut, where it can fully exert its benefits.

Guaranteed stability

The stability of Teoliance^®CBM588^® has been optimized through several key measures. The product is packaged in an opaque glass bottle designed to protect its contents from light and moisture. This opacity ensures the preservation of the strain’s properties throughout its shelf life. Additionally, the strain’s stability is certified for three years, validated by in-depth studies under normal conditions, providing consistent safety and efficacy until its expiration date.

Efficacy and safety

The Novel Food status, defined by European regulations, applies to foods or ingredients not significantly consumed within the European Union before May 15, 1997. To obtain this status, a product undergoes rigorous safety evaluation by the European Food Safety Authority (EFSA), including analyses of its composition, mechanism of action, safety, and absence of health risks.
Clostridium butyricum CBM588^® has achieved Novel Food status, allowing its commercialization in Europe, supported by a scientific dossier demonstrating its non-pathogenicity and safety as a probiotic strain. Toxicological and clinical studies confirm its safety, even at high doses. This status ensures the product complies with the highest European standards